Citrullinemia: Symptoms and Treatment

Citrullinemia is a rare genetic disorder characterized by the accumulation of ammonia and other toxic substances in the blood. This condition arises due to a deficiency of the enzyme argininosuccinate synthetase, which plays a crucial role in the urea cycle. The urea cycle is responsible for removing ammonia from the bloodstream, and its disruption leads to the severe health complications associated with citrullinemia.

---

What is Citrullinemia?

Citrullinemia is categorized as a urea cycle disorder (UCD), and it impairs the body’s ability to convert ammonia into urea, which is then excreted through urine. The accumulation of ammonia can be toxic, particularly to the brain, and can lead to severe neurological complications if not managed effectively.

---

Types of Citrullinemia

There are two primary types of citrullinemia: Type I (classic citrullinemia) and Type II.

Type I (Classic Citrullinemia)

Type I citrullinemia is typically diagnosed in newborns or infants and is caused by mutations in the ASS1 gene. This form is the most common and presents with severe symptoms shortly after birth.

Type II Citrullinemia

Type II citrullinemia, also known as adult-onset citrullinemia, is less common and usually presents in adulthood. It is linked to mutations in the SLC25A13 gene. Symptoms in Type II can be triggered by stress, illness, or certain medications.

---

Symptoms of Citrullinemia

Neonatal-Onset Symptoms

In newborns with Type I citrullinemia, symptoms often appear within the first few days of life and can include:

If left untreated, these symptoms can escalate to more severe complications such as coma or death.

Late-Onset Symptoms

In Type II citrullinemia, symptoms may not manifest until later in life and can be more varied. Common symptoms include:

Shared Symptoms

Both types of citrullinemia can present overlapping symptoms such as:

---

Causes of Citrullinemia

Genetic Mutations

Citrullinemia is an autosomal recessive disorder, meaning a child must inherit two copies of the mutated gene, one from each parent, to develop the condition. The ASS1 gene mutation is responsible for Type I, while the SLC25A13 gene mutation causes Type II.

Enzyme Deficiency

The mutations affect the enzymes involved in the urea cycle. In Type I, the deficiency of argininosuccinate synthetase disrupts the conversion of citrulline and aspartate into argininosuccinate, causing ammonia accumulation. In Type II, the mutation impairs the function of citrin, a protein that transports aspartate and glutamate across the mitochondrial membrane, leading to similar toxic buildups.

---

Diagnosis of Citrullinemia

Newborn Screening

Newborn screening tests are essential for early detection of Type I citrullinemia. These tests measure the levels of citrulline and ammonia in the blood, providing a quick diagnosis that can prompt immediate intervention.

Genetic Testing

Genetic testing can confirm the presence of mutations in the ASS1 or SLC25A13 genes. This testing is critical not only for diagnosis but also for family planning and genetic counseling.

Ammonia Levels

Elevated blood ammonia levels are a hallmark of citrullinemia. Measuring these levels helps in diagnosing the disorder and monitoring the effectiveness of treatment.

---

Management and Treatment of Citrullinemia

Dietary Management

A low-protein diet is often the cornerstone of managing citrullinemia, as it reduces the amount of ammonia produced from protein metabolism. Specialized formulas and dietary supplements can provide the necessary nutrients without exacerbating the condition.

Medications

Medications such as sodium phenylbutyrate and sodium benzoate can help reduce ammonia levels in the blood. These drugs work by providing alternative pathways for ammonia detoxification.

Liver Transplant

In severe cases, particularly for Type I citrullinemia, a liver transplant may be considered. This procedure can correct the enzyme deficiency and restore normal urea cycle function, offering a potential cure for the disorder.

Monitoring and Follow-Up

Regular monitoring of ammonia levels and ongoing follow-up with healthcare providers are crucial for managing citrullinemia. This ensures that any changes in the patient’s condition are promptly addressed and treatment plans are adjusted as necessary.

---

Prevention and Genetic Counseling

Carrier Screening

Carrier screening for potential parents can identify individuals who carry the mutated genes associated with citrullinemia. This information can guide family planning decisions and reduce the risk of having an affected child.

Prenatal Diagnosis

Prenatal genetic testing can diagnose citrullinemia before birth, allowing for early intervention and preparation for managing the condition postnatally.

Genetic Counseling

Genetic counseling provides families with information about the inheritance patterns, risks, and implications of citrullinemia. Counselors can offer support and resources to help families make informed decisions.